Results 31 to 40 of about 55,011 (304)
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin ...
Daria Ja’arah +4 more
doaj +1 more source
The effects of species ortholog and SNP variation on receptors for free fatty acids [PDF]
Although it is widely assumed that species orthologs of hormone responsive G protein-coupled receptors will be activated by the same endogenously produced ligand(s), variation in potency, particularly in cases where more than one receptor responds to the
1000 Genomes Project Consortium +72 more
core +1 more source
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate [PDF]
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed.
A Asmar +57 more
core +1 more source
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models.
Patrick J. Knerr +10 more
doaj +1 more source
G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets [PDF]
It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a number of cell-surface G-protein coupled receptors (GPCRs).
Brian D. Hudson +6 more
core +2 more sources
Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga +2 more
wiley +1 more source
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac +2 more
doaj +1 more source
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang +12 more
doaj +1 more source
Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents [PDF]
peer-reviewedThe gut hormone glucagon-like peptide (GLP)-1 and its analogues represent a new generation of anti-diabetic drugs, which have also demonstrated propensity to modulate host lipid metabolism.
Cryan, John F. +13 more
core +5 more sources

